This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 3.62% and 1.34%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Emerging Market Expansion Supports ZBH Stock Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
by Zacks Equity Research
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
ZBH Stock Might Rise Following FDA Nod for OsseoFit
by Zacks Equity Research
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Perrigo (PRGO) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain ZBH Stock in Your Portfolio for Now
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
by Zacks Equity Research
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Why Is Zimmer (ZBH) Up 4.8% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
by Zacks Equity Research
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval. The company plans a nationwide launch in the first quarter of 2025.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
by Zacks Equity Research
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.
ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed
by Zacks Equity Research
Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024.
Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of -0.57% and 1.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What to Expect From These 3 MedTech Stocks This Earnings Season
by Urmimala Biswas
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
by Zacks Equity Research
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
by Zacks Equity Research
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.